Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $5.2 million.

  • Maxcyte's Current Deferred Revenue fell 2189.99% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 2189.99%. This contributed to the annual value of $5.3 million for FY2024, which is 359.05% up from last year.
  • Per Maxcyte's latest filing, its Current Deferred Revenue stood at $5.2 million for Q3 2025, which was down 2189.99% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, Maxcyte's Current Deferred Revenue peaked at $7.3 million during Q2 2022, and registered a low of $2.6 million during Q2 2025.
  • In the last 5 years, Maxcyte's Current Deferred Revenue had a median value of $5.7 million in 2023 and averaged $5.5 million.
  • In the last 5 years, Maxcyte's Current Deferred Revenue skyrocketed by 3931.03% in 2021 and then plummeted by 3581.1% in 2023.
  • Quarter analysis of 5 years shows Maxcyte's Current Deferred Revenue stood at $6.7 million in 2021, then dropped by 0.5% to $6.7 million in 2022, then decreased by 24.49% to $5.1 million in 2023, then grew by 3.59% to $5.3 million in 2024, then dropped by 1.05% to $5.2 million in 2025.
  • Its Current Deferred Revenue stands at $5.2 million for Q3 2025, versus $2.6 million for Q2 2025 and $4.1 million for Q1 2025.